Objective: The purpose of this study was to determine whether the recommended waiting period of 3 months is necessary for repeat fine-needle aspiration biopsy (FNAB). Study Design: A retrospective review of 128 nodules from 126 patients with initial nondiagnostic (ND) results was performed for the period between January 2009 and December 2012. Demographic and clinical factors were recorded including age, sex, time interval between FNABs, and ultrasound (US) factors, i.e. nodule size, location, consistency, suspicious malignant findings and thyroiditis. The time interval was subdivided into </≥5, 10, 15 and 20 weeks after the initial FNAB. The effects on the nuclear atypia were analyzed using the Fisher exact test and the Mann-Whitney U test. Results: None of the demographic, clinical or US variables was significantly related to the atypical diagnosis of repeat FNAB. The time interval until repeat FNAB was also not related to the atypical diagnosis (p = 0.63, 0.57, 0.23 and 0.48 for 5, 10, 15 and 20 weeks, respectively). Conclusion: The timing of repeat FNAB for thyroid nodules with previous ND results did not increase the nuclear atypia on repeat FNAB.

Keywords:
Thyroid nodules, Repeat fine-needle aspiration, Nuclear atypia
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.